Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin + Pioglitazone in Type 2 Diabetes
NCT00099853Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2004
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vildagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline in HbA1c at 24 weeks. Started May 2004; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00099853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099853.